The Pleasanton, Calif.-based robot-assisted surgery device maker posted profits of $211.0 million, or $5.31 per share, on sales growth of 15.8% to $682.9 million for the 3 months ended Sept. 30, for bottom-line growth of 26.1% compared with Q3 2015.
Adjusted to exclude 1-time items, earnings per share were $6.19, a full $1.06 ahead of The Street, where analysts were looking for sales of $650.5 million.
Intuitive also said it inked a co-development deal with China’s Shanghai Fosun Pharmaceutical to work on robot-assisted, catheter-based medical devices for the early diagnosis and treatment of lung cancer.
“While we are pleased with our 3rd-quarter operating results, we remain focused on helping our customers build effective robotic surgery programs by understanding their needs and delivering the right products and services,” president & CEO Gary Guthart said in prepared remarks.
ISRG shares closed up 1.7% at $721.73 apiece today and gained another 1.2% after hours, rising to $730 even per share.